New Hope for Patients with Parkinson's Disease
Pioneering Brain-Targeted Therapies
Our groundbreaking SNL-based technology delivers precision therapies directly to affected brain structures. Through innovative intranasal delivery, we're not just managing Parkinson's disease—we're aiming to modify its course.
Join us in reshaping the future of neurological care.
One of the greatest challenges in treating neurodegenerative diseases, such as Parkinson’s, is the effective delivery of therapeutic agents to the brain. Nutaria's proprietary intranasal nanotechnology overcomes the blood-brain barrier (BBB), allowing precise, targeted delivery of active ingredients directly to specific brain structures affected by the disease. This breakthrough approach ensures that therapeutic compounds reach areas most impacted by neurodegeneration, enabling a more effective treatment strategy. By targeting delivery, we offer a transformative step forward in modifying disease progression and improving patient outcomes.
Latest News
September 2024
The upcoming study, titled Evaluation of NT501 Delivery to the Brain in Advanced Parkinson’s Disease Models, will be conducted with LIOS, an internationally renowned institute for pharmacological research. Having established the protocol, we are set to initiate the study within weeks. Its successful completion will position Nutaria for the next funding round, with clinical trials scheduled to begin in early 2027.
April 2024
Nutaria has achieved a pivotal milestone with the successful completion of an intranasal study on NT501 at LIOS. Results demonstrated precise delivery to critical brain regions, with significant accumulation of the active ingredient in Parkinson's-associated areas. This breakthrough validates our innovative nose-to-brain delivery system's efficacy, paving the way for our next development phase.
Collaborative Partners
Nutaria is proud to present part of our collaborating partners, all joining us in the journey to achieve our innovative vision
Endorsed by the Israeli Parkinson's Association
*Collaboration with Iff was achieved via the Innovation Laboratory Funding track by the Israeli Innovation Authority.